Clinical Trials

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH Phase II Clinical Study

🕔10/5/2022 8:58:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Receives Ethics Approval for US Clinical Study

🕔9/26/2022 8:54:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has received ethics approval to proceed with a US pharmacokinetics and exercise clinical study.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient

🕔9/14/2022 8:50:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).

Read Full Article

VGI Health Technology Limited (NSX:VTL) June 2022 Quarterly Update

🕔7/29/2022 8:57:00 AM

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 June 2022.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Clinical Study Begins Recruitment of Patients

🕔7/5/2022 9:29:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has commenced recruitment of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic SteatoHepatitis.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Binding Sale Agreement of Subsidiary

🕔4/6/2022 8:50:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has today executed a binding agreement for the sale of its wholly owned subsidiary Invictus BioPharma Pty Ltd.

Read Full Article

VGI Health Technology Limited (NSX:VTL) US Divisional Patent to be Granted

🕔4/4/2022 7:44:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that the United States Patent and Trademarks Office (USPTO) intends to grant a divisional patent for the 'Transmucosal Delivery of Tocotrienols' to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd.

Read Full Article